Aquestive Therapeutics, Inc. (AQST)
4.07
+0.10
(+2.52%)
USD |
NASDAQ |
Oct 27, 16:00
4.08
+0.01
(+0.25%)
After-Hours: 07:52
Aquestive Therapeutics Enterprise Value : 561.43M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 561.43M |
| October 26, 2026 | 548.88M |
| October 23, 2026 | 552.64M |
| October 22, 2026 | 568.96M |
| October 21, 2026 | 562.68M |
| October 20, 2026 | 558.92M |
| October 19, 2026 | 531.30M |
| October 16, 2026 | 525.03M |
| October 15, 2026 | 560.17M |
| October 14, 2026 | 629.20M |
| October 13, 2026 | 636.73M |
| October 12, 2026 | 654.31M |
| October 09, 2026 | 650.54M |
| October 08, 2026 | 648.03M |
| October 07, 2026 | 630.46M |
| October 06, 2026 | 629.20M |
| October 05, 2026 | 624.18M |
| October 02, 2026 | 621.67M |
| October 01, 2026 | 607.87M |
| September 30, 2026 | 631.71M |
| September 29, 2026 | 636.73M |
| September 28, 2026 | 646.78M |
| September 25, 2026 | 637.99M |
| September 24, 2026 | 655.56M |
| September 23, 2026 | 640.50M |
| Date | Value |
|---|---|
| September 22, 2026 | 671.88M |
| September 21, 2026 | 650.54M |
| September 18, 2026 | 629.20M |
| September 17, 2026 | 635.48M |
| September 16, 2026 | 655.56M |
| September 15, 2026 | 654.31M |
| September 14, 2026 | 663.09M |
| September 11, 2026 | 650.54M |
| September 10, 2026 | 676.90M |
| September 09, 2026 | 696.98M |
| September 08, 2026 | 704.51M |
| September 04, 2026 | 720.83M |
| September 03, 2026 | 722.08M |
| September 02, 2026 | 725.85M |
| September 01, 2026 | 708.28M |
| August 31, 2026 | 691.96M |
| August 28, 2026 | 680.66M |
| August 27, 2026 | 698.23M |
| August 26, 2026 | 727.10M |
| August 25, 2026 | 688.19M |
| August 24, 2026 | 653.05M |
| August 21, 2026 | 635.48M |
| August 20, 2026 | 614.77M |
| August 19, 2026 | 626.69M |
| August 18, 2026 | 592.81M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eton Pharmaceuticals, Inc. | 1.450B |
| LENZ Therapeutics, Inc. | -120.47M |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.86M |
| Revenue (Quarterly) | 13.82M |
| Total Expenses (Quarterly) | 36.68M |
| EPS Diluted (Quarterly) | -0.1829 |
| Gross Profit Margin (Quarterly) | 70.93% |
| Profit Margin (Quarterly) | -165.5% |
| Earnings Yield | -15.96% |
| Normalized Earnings Yield | -14.35 |